Ann Mullally
Overview
Explore the profile of Ann Mullally including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
69
Citations
3369
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Faiz M, Riedemann M, Jutzi J, Mullally A
Curr Hematol Malig Rep
. 2025 Jan;
20(1):4.
PMID: 39775969
Purpose Of Review: More than a decade following the discovery of Calreticulin (CALR) mutations as drivers of myeloproliferative neoplasms (MPN), advances in the understanding of CALR-mutant MPN continue to emerge....
2.
Hormoz S, Sankaran V, Mullally A
Haematologica
. 2024 Dec;
PMID: 39633553
Over the course of the last decade, genomic studies in the context of normal human hematopoiesis have provided new insights into the early pathogenesis of myeloproliferative neoplasms (MPN). A preclinical...
3.
Kramer F, Mullally A
J Cell Mol Med
. 2023 Aug;
28(5):e17896.
PMID: 37551061
Mutations in calreticulin are one of the key disease-initiating mutations in myeloproliferative neoplasms (MPN). In MPN, mutant calreticulin translates with a novel C-terminus that leads to aberrant binding to the...
4.
5.
How J, Garcia J, Mullally A
Blood
. 2022 Dec;
141(16):1922-1933.
PMID: 36534936
Myeloproliferative neoplasms (MPNs) are clonal hematopoietic stem cell disorders characterized by activated Janus kinase (JAK)-signal transducer and activator of transcription signaling. As a result, JAK inhibitors have been the standard...
6.
Jutzi J, Marneth A, Jimenez-Santos M, Hem J, Guerra-Moreno A, Rolles B, et al.
Leukemia
. 2022 Dec;
37(2):359-369.
PMID: 36473980
Cancer is driven by somatic mutations that provide a fitness advantage. While targeted therapies often focus on the mutated gene or its direct downstream effectors, imbalances brought on by cell-state...
7.
Rolles B, Mullally A
Curr Hematol Malig Rep
. 2022 Nov;
17(6):319-329.
PMID: 36336766
Purpose Of Review: Myeloproliferative neoplasms (MPNs) are chronic hematological malignancies characterized by increased proliferation of MPN stem and myeloid progenitor cells with or without bone marrow fibrosis that typically lead...
8.
Vining K, Marneth A, Adu-Berchie K, Grolman J, Tringides C, Liu Y, et al.
Nat Mater
. 2022 Jul;
21(8):939-950.
PMID: 35817965
Myelofibrosis is a progressive bone marrow malignancy associated with monocytosis, and is believed to promote the pathological remodelling of the extracellular matrix. Here we show that the mechanical properties of...
9.
Jutzi J, Marneth A, Ciboddo M, Guerra-Moreno A, Jimenez-Santos M, Kosmidou A, et al.
Blood
. 2022 Jun;
140(11):1291-1304.
PMID: 35763665
Calreticulin (CALR) mutations are frequent, disease-initiating events in myeloproliferative neoplasms (MPNs). Although the biological mechanism by which CALR mutations cause MPNs has been elucidated, there currently are no clonally selective...
10.
Gigoux M, Holmstrom M, Zappasodi R, Park J, Pourpe S, Bozkus C, et al.
Sci Transl Med
. 2022 Jun;
14(649):eaba4380.
PMID: 35704596
The majority of JAK2-negative myeloproliferative neoplasms (MPNs) have disease-initiating frameshift mutations in calreticulin (), resulting in a common carboxyl-terminal mutant fragment (CALR), representing an attractive source of neoantigens for cancer...